<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesJohn S. Welch, Timothy J. Ley, Allegra A. Petti et al.|New England Journal of Medicine|2016Cited by 783
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Peter Valent, Daniel J. Lenihan et al.|European Heart Journal|2021Cited by 589
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular TherapyMohamed A. Kharfan‐Dabaja, Marcie Riches, Suzanne Fanning et al.|Transplantation and Cellular Therapy|2021Cited by 180
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for LeukemiaMelissa M. Berrien-Elliott, Todd A. Fehniger, Amanda F. Cashen et al.|Cancer Discovery|2020Cited by 146
Mutation Clearance after Transplantation for Myelodysplastic SyndromeEric J. Duncavage, Matthew J. Walter, Meagan A. Jacoby et al.|New England Journal of Medicine|2018Cited by 121